-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chronic lymphocytic leukemia (CLL, chronic lymphocytic leukemia) is a blood and bone marrow cancer that exists in different forms and occurs for a variety of reasons.
CLL can exist as a slow- or fast-growing cancer that is thought to be associated with specific genetic mutations that have not been fully elucidated.
To construct the map, the researchers analyzed changes in the genetic sequence, gene expression patterns, chemical modifications of DNA—that is, data related to the genome, transcriptome, and epigenetic group—from 1,148 patients.
Image source: https://pubmed.
In the article, the researchers identified 202 genes (109 of which were newly discovered genes) whose mutations could potentially drive the development of CLL, and the researchers refined CLL subtypes with different genomic features and prognosis In addition to genetic sequences, the expression patterns of specific genes can also help scientists to further classify CLL and can provide valuable prognostic information; the results of this study suggest that the genetic and biological blueprint of CLL may be stronger than previously thought more complicated
A patient's clinical outcome is associated with a combination of genomic, transcriptomic, and epigenetic features, so integrating these data may help predict the likelihood that a patient will experience the disease and progress to a malignant cancer
Original source:
Knisbacher, BA, Lin, Z.
